Eur Rev Med Pharmacol Sci 1999; 3 (2): 63-69

Lithium safety in the prophylaxis of bipolar disorders: a study with plasma levels

M.C. Mauri, V. Laini, M.E. Scalvini, L.S. Volonteri, M.S. Ferrari, G. Panza

Department of Clinical Psichiatry, Clinical Neuropsychopharmacology Unit, University of Milan, IRCCS, Ospedale Maggiore – Milan (Italy)


Abstract. – From many decades efficacy of lithium salts, as mood stabilizers, has been largely recognized, but their tolerability, in particular during intermediate or long-term treatments is still discussed. The most frequently described side effects can affect several organs. Aim of the study was to evaluate lithium carbonate tolerability after a “brief” (1 month-4 years), “intermediate” (5-9 years) and “long-term” (10-21 years) treatment of patients affected by Bipolar Disorders (BD). 27 patients (14 males, 13 females), aged from 20 to 78 years (mean 49.03 years +/- 14.61 SD), affected by BD, type I, according to DSM IV criteria were included into the study. Our data suggest a good tolerability of lithium salts without significant differences among the three different periods of treatment.

Free PDF Download

To cite this article

M.C. Mauri, V. Laini, M.E. Scalvini, L.S. Volonteri, M.S. Ferrari, G. Panza
Lithium safety in the prophylaxis of bipolar disorders: a study with plasma levels

Eur Rev Med Pharmacol Sci
Year: 1999
Vol. 3 - N. 2
Pages: 63-69